← Leaderboards
Robert H Weiss
University Of California Davis
$3,328,356
Attributed
$3,328,356
Total exposure
5
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $663.4K · FY2009–18$1M$750K$500K$250K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
Funding mix
By agency
NIH$3,328,356 · 5
By mechanism
R01$2,875,981 · 3
R21$296,875 · 1
R03$155,500 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of California Davis
Same institution · by research overlap
- Martin L. Privalsky$7,643,726
- Douglas G Matsell$597,401
Others in their field
Top investigators on “Metabolic”
- David M Nathan · Massachusetts Institute Of Technology$157,845,616
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$144,157,234
- Judith S. Currier · University Of California Los Angeles$141,260,706
- John M Lachin · George Washington University$139,991,329
- Randall J Bateman · Washington University$124,168,384
- Carol Nesel · Westat$116,355,411
Research focus
MetabolicBaseUrinaryTechnologyResearch StudyRenal CarcinomaMetabolic PathwayMetabolomicsStagingPatternKidneyLeadKidney DiseasesClinicDetectionPrimary Health CareScientistTreatment ProtocolsPathway InteractionsPathway AnalysisGleanGrantInstitutionUrine
Grant awards (14)
A Metabolomic Approach to Discovering Markers for ADPKD Progression$210,884
R01 · FY2018 · DK · contact PI
A Metabolomic Approach to Discovering Markers for ADPKD Progression$210,881
R01 · FY2017 · DK · contact PI
A Metabolomic Approach to Discovering Markers for ADPKD Progression$218,522
R01 · FY2016 · DK · contact PI
The addition of fish oil to sorafenib may prevent kidney cancer metastasis$78,000
R03 · FY2015 · CA · contact PI
The addition of fish oil to sorafenib may prevent kidney cancer metastasis$77,500
R03 · FY2014 · CA · contact PI
Metabolomic discovery and validation of urinary biomarkers for kidney cancer$291,367
R01 · FY2013 · CA · contact PI
Metabolomic discovery and validation of urinary biomarkers for kidney cancer$309,890
R01 · FY2012 · CA · contact PI
Metabolomic discovery and validation of urinary biomarkers for kidney cancer$308,622
R01 · FY2011 · CA · contact PI
A Metabolomic Approach to Discovering Biomarkers for ADPKD$345,928
R01 · FY2010 · DK · contact PI
Metabolomic discovery and validation of urinary biomarkers for kidney cancer$317,475
R01 · FY2010 · CA · contact PI
A Metabolomic Approach to Discovering Biomarkers for ADPKD$350,000
R01 · FY2009 · DK · contact PI
Metabolomic discovery and validation of urinary biomarkers for kidney cancer$312,412
R01 · FY2009 · CA · contact PI
Cyclin Kinase Inhibitors as Molecular Targets for Cancer$148,500
R21 · FY2003 · CA
Cyclin Kinase Inhibitors as Molecular Targets for Cancer$148,375
R21 · FY2002 · CA